Last Updated:
'Red Tape, Confusion': EU Accidentally Blocks Cancer Drug Citing Brexit Law, NI Protocol
The drug, used to treat non-small cell cancer, was supposed to have approval by the EU's European Medicines Agency (EMA) last month but was stalled.
IMAGE: AP
EU has ‘accidentally blocked’ the UK authorized critical lung cancer drug as it moved the production to Dublin citing the Brexit red tape on the exports, the Northern Ireland protocol, and other arrangements of the post-Brexit deal, according to UK's press reports. South African pharmaceutical company Aspen, on Saturday, incurred wastage of hundreds of vital packages of the medication called Osimertinib sold under brand name Tagrisso for cancer treatment, after EU told the firm that it cannot be authorized under an international scheme.